XLRN stock forecast
Our latest prediction for Acceleron Pharma, Inc.'s stock price was made on the Jan. 3, 2020 when the stock price was at 50.95$.
In the short term (2weeks), XLRN's stock price should underperform the market by -4.49%. During that period the price should oscillate between -9.29% and +7.83%.
In the medium term (3months), XLRN's stock price should underperform the market by -10.03%. During that period the price should oscillate between -34.98% and +22.07%.Get email alerts
Create a solid portfolio with XLRN
About Acceleron Pharma, Inc.
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.
At the moment the company generates 88M USD in revenues.
On its last earning announcement, the company reported a loss of -2.59$ per share.
The book value per share is 7.24$
Three months stock forecastJan. 3, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|